Contact
searchSearch
HMP Global
Login

Small Cell Lung Cancer

Small Cell Lung Cancer
Specialty Channel
News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter...
07/09/2026
Oncology
News
Durvalumab Plus Anlotinib Maintenance Improves PFS in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with...
07/02/2026
Oncology
News
Serplulimab Plus Chemotherapy Shows Sustained Survival Benefit in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Updated results from the phase 3 ASTRUM-005 trial demonstrated that serplulimab plus carboplatin and etoposide continued to improve long-term overall survival compared with chemotherapy alone in patients with previously untreated...
Updated results from the phase 3 ASTRUM-005 trial demonstrated that serplulimab plus carboplatin and etoposide continued to improve long-term overall survival compared with chemotherapy alone in patients with previously untreated...
Updated results from the phase 3...
07/02/2026
Oncology
News
Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Results from a real-world study demonstrated that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer,...
Results from a real-world study demonstrated that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer,...
Results from a real-world study...
07/02/2026
Oncology
Quiz
Tiragolumab Plus Atezolizumab and Chemotherapy in ES-SCLC
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
News
Ivonescimab Plus Liposomal Irinotecan Demonstrates Second-Line Promise in Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
177Lu-Satoreotide Tetraxetan Shows Strong Preliminary Efficacy and Safety in Extensive-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1...
06/09/2026
Oncology
News
Autologous NK Cell Consolidation Improves Survival Outcomes in Limited-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
Tiragolumab Plus Atezolizumab and Chemotherapy in Extensive-Stage Small Cell Lung Cancer
05/19/2026
Emily Estrada
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3...
05/19/2026
Oncology
News
Tarlatamab Resistance in Small Cell Lung Cancer Linked to DLL3 Downregulation and Immune Exhaustion
05/07/2026
Emily Estrada
Results from a case-based translational analysis indicate that acquired resistance to tarlatamab in patients with extensive-stage small cell lung cancer may be driven by tumor antigen loss and tumor microenvironment changes.
Results from a case-based translational analysis indicate that acquired resistance to tarlatamab in patients with extensive-stage small cell lung cancer may be driven by tumor antigen loss and tumor microenvironment changes.
Results from a case-based...
05/07/2026
Oncology

News

News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter...
07/09/2026
Oncology
News
Durvalumab Plus Anlotinib Maintenance Improves PFS in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with...
07/02/2026
Oncology
News
Serplulimab Plus Chemotherapy Shows Sustained Survival Benefit in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Updated results from the phase 3 ASTRUM-005 trial demonstrated that serplulimab plus carboplatin and etoposide continued to improve long-term overall survival compared with chemotherapy alone in patients with previously untreated...
Updated results from the phase 3 ASTRUM-005 trial demonstrated that serplulimab plus carboplatin and etoposide continued to improve long-term overall survival compared with chemotherapy alone in patients with previously untreated...
Updated results from the phase 3...
07/02/2026
Oncology
News
Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Results from a real-world study demonstrated that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer,...
Results from a real-world study demonstrated that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer,...
Results from a real-world study...
07/02/2026
Oncology
News
Ivonescimab Plus Liposomal Irinotecan Demonstrates Second-Line Promise in Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
177Lu-Satoreotide Tetraxetan Shows Strong Preliminary Efficacy and Safety in Extensive-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1...
06/09/2026
Oncology
News
Autologous NK Cell Consolidation Improves Survival Outcomes in Limited-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
Tiragolumab Plus Atezolizumab and Chemotherapy in Extensive-Stage Small Cell Lung Cancer
05/19/2026
Emily Estrada
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3...
05/19/2026
Oncology
News
Tarlatamab Resistance in Small Cell Lung Cancer Linked to DLL3 Downregulation and Immune Exhaustion
05/07/2026
Emily Estrada
Results from a case-based translational analysis indicate that acquired resistance to tarlatamab in patients with extensive-stage small cell lung cancer may be driven by tumor antigen loss and tumor microenvironment changes.
Results from a case-based translational analysis indicate that acquired resistance to tarlatamab in patients with extensive-stage small cell lung cancer may be driven by tumor antigen loss and tumor microenvironment changes.
Results from a case-based...
05/07/2026
Oncology

Interactive Features

Quiz
Tiragolumab Plus Atezolizumab and Chemotherapy in ES-SCLC
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
Sequential Thoracic Radiotherapy After Chemoimmunotherapy in ES-SCLC
04/02/2026
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage...
04/02/2026
Oncology
Quiz
Serum LDH and α-HBDH Levels in SCLC
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
Quiz
Predictive Accuracy of Whole-Brain Radiotherapy Response in SCLC With Brain Metastases
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology
Quiz
ISL1 as a Predictive Biomarker for Lurbinectedin Efficacy in Small Cell Lung Cancer
02/05/2026
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging...
02/05/2026
Oncology
Quiz
Berzosertib Plus Topotecan vs Topotecan Monotherapy for SCLC
01/27/2026
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent...
01/27/2026
Oncology
Quiz
Evaluating Pembrolizumab Plus Chemotherapy in Extensive SCLC
12/17/2025
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed...
12/17/2025
Oncology
Quiz
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
12/10/2025
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following...
12/10/2025
Oncology
Quiz
Tarlatamab for Extensive-Stage Small Cell Lung Cancer
11/24/2025
Based on results from the phase 3 DeLLphi-304 trial, the FDA has granted traditional approval to tarlatamab for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Which of the following statements best summarizes...
Based on results from the phase 3 DeLLphi-304 trial, the FDA has granted traditional approval to tarlatamab for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Which of the following statements best summarizes...
Based on results from the phase...
11/24/2025
Oncology
Quiz
Optimal Olaparib Dose Added to Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer
10/29/2025
Do you know the optimal olaparib dose in addition to thoracic radiation therapy for patients with extensive-stage small cell lung cancer? Test your knowledge with our quick quiz!
Do you know the optimal olaparib dose in addition to thoracic radiation therapy for patients with extensive-stage small cell lung cancer? Test your knowledge with our quick quiz!
Do you know the optimal olaparib...
10/29/2025
Oncology

Recent News

News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter...
07/09/2026
Oncology
News
Durvalumab Plus Anlotinib Maintenance Improves PFS in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with...
07/02/2026
Oncology
News
Serplulimab Plus Chemotherapy Shows Sustained Survival Benefit in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Updated results from the phase 3 ASTRUM-005 trial demonstrated that serplulimab plus carboplatin and etoposide continued to improve long-term overall survival compared with chemotherapy alone in patients with previously untreated...
Updated results from the phase 3 ASTRUM-005 trial demonstrated that serplulimab plus carboplatin and etoposide continued to improve long-term overall survival compared with chemotherapy alone in patients with previously untreated...
Updated results from the phase 3...
07/02/2026
Oncology
News
Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Results from a real-world study demonstrated that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer,...
Results from a real-world study demonstrated that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer,...
Results from a real-world study...
07/02/2026
Oncology
News
Ivonescimab Plus Liposomal Irinotecan Demonstrates Second-Line Promise in Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
177Lu-Satoreotide Tetraxetan Shows Strong Preliminary Efficacy and Safety in Extensive-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1...
06/09/2026
Oncology
News
Autologous NK Cell Consolidation Improves Survival Outcomes in Limited-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
Tiragolumab Plus Atezolizumab and Chemotherapy in Extensive-Stage Small Cell Lung Cancer
05/19/2026
Emily Estrada
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3...
05/19/2026
Oncology
News
Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use